Camp4 Therapeutics (CAMP) Net Margin (2023 - 2026)

Camp4 Therapeutics has disclosed Net Margin across 4 years of filings, most recently posting 939.8% for Q1 2026.

• Net Margin for Q1 2026 came in at 939.8%, up 51848.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1271.73% (up 215250.0% YoY), and the FY2025 annual result was 1445.77%, up 649764.0% from the prior year.
• Net Margin came in at 939.8% for Q1 2026 at Camp4 Therapeutics, up from 3467.24% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 840.01% in Q2 2025 to a low of 3467.24% in Q4 2025.
• The 4-year median for Net Margin is 1663.9% (2025), against an average of 1963.94%.
• Across the five-year window, Net Margin tumbled 143058 bps in 2025 and surged 51848 bps in 2026, its largest moves.
• Camp4 Therapeutics' Net Margin stood at 3341.71% in 2023, then soared by 39 bps to 2036.66% in 2024, then sank by 70 bps to 3467.24% in 2025, then surged by 73 bps to 939.8% in 2026.
• The last three Net Margin figures came in at 939.8% (Q1 2026), 3467.24% (Q4 2025), and 1663.9% (Q3 2025), per Business Quant data.